Proton pump inhibitor medications
Pro Research Analysisby 
Searched over 200M research papers
Proton Pump Inhibitor Medications: Uses, Risks, and Emerging Concerns
Introduction to Proton Pump Inhibitors (PPIs)
Proton pump inhibitors (PPIs) are among the most widely prescribed medications globally, primarily used to treat acid-related gastrointestinal disorders such as peptic ulcer disease, gastroesophageal reflux disease (GERD), and nonulcer dyspepsia Nehra2018Perry2020. These medications work by irreversibly inhibiting the hydrogen/potassium pump (H+/K+-ATPase pump) in gastric parietal cells, thereby reducing gastric acid secretion .
Overprescription and Economic Impact
Despite their effectiveness, PPIs are often overprescribed, leading to unnecessary economic costs and contributing to polypharmacy . Overuse of PPIs is particularly concerning given the increasing evidence of potential adverse effects associated with long-term use Ali2009Nehra2018Schoenfeld2016.
Adverse Effects of Long-term PPI Use
Nutritional Deficiencies and Bone Health
Long-term PPI use has been linked to several nutritional deficiencies, including hypomagnesemia, vitamin B12 deficiency, and iron deficiency Bridoux2022Nehra2018Fossmark2019. These deficiencies can lead to significant health issues, such as bone loss and an increased risk of osteoporotic-related fractures, particularly in older adults .
Infectious Complications
PPIs have been associated with an increased risk of infectious complications, including Clostridium difficile infection and community-acquired pneumonia Ali2009Nehra2018Maes2017. The reduction in gastric acid secretion can disrupt the gut microbiota, leading to dysbiosis and increased susceptibility to infections .
Chronic Kidney Disease and Other Risks
Emerging data suggest a potential link between long-term PPI use and chronic kidney disease, as well as other serious conditions such as dementia and chronic liver disease Schoenfeld2016Li2018Fossmark2019. However, the evidence is primarily observational, and further research is needed to establish definitive causal relationships Nehra2018Fossmark2019.
PPIs and Cancer
The relationship between PPI use and cancer is complex and not fully understood. Some studies suggest that PPIs may have both pro-tumor and anti-tumor activities, depending on the context . For instance, PPIs may decrease the efficacy of certain antineoplastic agents through drug-drug interactions (DDIs) and may interact with the cancer microbiome, potentially affecting cancer treatment outcomes .
De-prescribing PPIs: Best Practices
Given the potential risks associated with long-term PPI use, de-prescribing strategies are essential. The American Gastroenterological Association (AGA) provides several best practice advice (BPA) statements for de-prescribing PPIs in ambulatory patients :
- Regular Review: All patients on PPIs should have their ongoing indications for use regularly reviewed by their primary care provider.
- Trial of De-prescribing: Patients without a definitive indication for chronic PPI use should be considered for a trial of de-prescribing.
- Step-down Therapy: Patients on twice-daily dosing should be considered for step-down to once-daily PPI.
- Special Populations: Patients with complicated GERD, Barrett's esophagus, eosinophilic esophagitis, or idiopathic pulmonary fibrosis should generally not be considered for PPI discontinuation.
- Upper GI Bleeding Risk: Patients should be assessed for upper gastrointestinal bleeding risk before de-prescribing.
Conclusion
While PPIs have revolutionized the treatment of acid-related disorders, their long-term use is associated with several potential adverse effects. Regular review of PPI indications and appropriate de-prescribing strategies are crucial to minimize risks and ensure patient safety. Further research is needed to fully understand the long-term implications of PPI use and to optimize their use in clinical practice.
Sources and full results
Most relevant research papers on this topic